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Abstract
Contrast-enhanced ultrasound (CEUS) is an emerging technique to evaluate tissue perfu-
sion. Promising results have been obtained in the evaluation of renal perfusion in health
and disease, both in human and veterinary medicine. Renal scintigraphy using 99mTc-Mer-
captoacetyltriglycine (MAG3) is another non-invasive technique that can be used to evalu-
ate renal perfusion. However, no data are available on the ability of CEUS or 99mTc- MAG3
scintigraphy to detect small changes in renal perfusion in cats. Therefore, both techniques
were applied in a normal feline population to evaluate detection possibilities of perfusion
changes by angiotensin II (AT II). Contrast-enhanced ultrasound using a bolus injection of
commercially available contrast agent and renal scintigraphy using 99mTc-MAG3 were per-
formed in 11 healthy cats after infusion of 0,9% NaCl (control) and AT II. Angiotensin II
induced changes were noticed on several CEUS parameters. Mean peak enhancement,
wash-in perfusion index and wash-out rate for the entire kidney decreased significantly
after AT II infusion. Moreover, a tendency towards a lower wash-in area-under-the curve
was present. Renal scintigraphy could not detect perfusion changes induced by AT II. This
study shows that CEUS is able to detect changes in feline renal perfusion induced by AT II
infusion.
PLOS ONE | DOI:10.1371/journal.pone.0164488 October 13, 2016 1 / 14
a11111
23(1$&&(66
Citation: Stock E, Vanderperren K, Bosmans T,
Dobbeleir A, Duchateau L, Hesta M, et al. (2016)
Evaluation of Feline Renal Perfusion with Contrast-
Enhanced Ultrasonography and Scintigraphy. PLoS
ONE 11(10): e0164488. doi:10.1371/journal.
pone.0164488
Editor: Douglas Thamm, Colorado State University,
UNITED STATES
Received: June 22, 2016
Accepted: September 26, 2016
Published: October 13, 2016
Copyright:  2016 Stock et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This research was supported by the
Special Research Fund of Ghent University,
Belgium (BOF grant 2015003301). The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Chronic kidney disease is of major importance in both human and veterinarymedicine with a
prevalence of 13% in people and even up to 50% in randomly selected cats, increasing to 68,8%
in cats with degenerative joint disease [1–3]. It is a progressive disorder with often an unclear
etiology. Early diagnosis is essential as intervention in early stage of the disease process pro-
vides better life expectancy and quality [4]. The assessment of renal perfusion is an important
component in the evaluation of kidney disease as these renal perfusion changes occur in early
state of the disease progress [5].
However, performing an accurate, noninvasive measurement of renal perfusion is challeng-
ing. The gold standard to estimate renal plasma flow is determination of para-amino hippuric
acid (PAH) clearance, although this is technically laborious and requires specific equipment,
limiting the use in clinical circumstances.
Renal perfusion can also be evaluated using radioactive tracers: ortho-iodo-hippuric acid
(OIH) and mercaptoacethyltriglycerine (MAG3). Both tracers have high first-pass extraction
rate, but do not reach an extraction rate of 100%, thus the term ‘effective renal plasma flow’
(ERPF) is used. Ortho-iodo-hippuric acid has a similar chemical structure to PAH, and can be
bound to 123I or 131I. Although the disadvantage is poor quality images compromising quantifi-
cation, the tracer is still useful for blood clearance techniques [6]. Mercaptoacetyltriglycine can
be labeled with 99mTc, making it a good tracer for imaging procedures [6]. Despite its 30%
lower clearance compared to OIH, high agreement between both tracers was found in both
humans and dogs [7, 8]. Significant hepatic uptake of MAG3 is noted in cats, thus requiring
camera-based investigation as they allow distinction of the separate organs. Some limitations
are associated with the use of radioactive tracers, including costs, involvement of radiation, and
limited equipment availability.
Contrast-enhanced ultrasound is a functional ultrasound technique that allows assessment
of both macro- and microcirculation.Ultrasound contrast agent consists of tiny gas-filled bub-
bles (microbubbles) that have a rheology similar to red blood cells after intravenous injection.
It is an extremely safe, cost-effective technique, which does not involve the use of ionizing radi-
ation [9, 10]. The rate of adverse effects is close to zero, and, in contrast to iodinated contrast
agents used in computed tomography or gadolinium-based contrast agent used in magnetic
resonance imaging, no nephrotoxicity is involved, allowing safe use in geriatric and pediatric
patients and patients with renal insufficiency [9]. Several studies in human medicine have
shown promising results for the use of CEUS in the diagnosis of diffuse renal disorders, such as
early assessment of chronic kidney dysfunction, diabetic kidney damage, and rejection of renal
transplants [11–15]. In dogs, CEUS was proven to be useful for the early detection of iatrogenic
chronic ischemic renal disease and to detect diffuse renal changes in beagles with iatrogenic
hypercortisolism [16, 17]. Nevertheless, it remains unclear if small changes in renal perfusion
can be detected using a bolus injection of ultrasound contrast agent in cats.
The objective of this study was to investigate the ability of CEUS and renal scintigraphy
using 99mTc-MAG3 to detect changes in renal perfusion of healthy cats at baseline and during
infusion of angiotensin II (AT II, an arterial vasoconstrictor).
Materials and Methods
Animals
The study was carried out in strict accordance with the recommendations of the European
Convention for the Protection of Vertebrate Animals used for Experimental and other Scien-
tific Purposes. The protocol was approved by the Ethical Committee of the Faculty of
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Veterinary Medicine of Ghent University (EC2014/38). All efforts were made to minimize suf-
fering. During the experiments, the cats were continuously monitored by experienced veteri-
narians to assess basic clinical parameters and signs of discomfort. Since suffering was limited
and no detrimental effect on further life quality was present, the cats are further kept as experi-
mental animals.
Eleven healthy purpose-bredEuropean Shorthair cats (Charles River Laboratories (30/
3202), France and Lab of animal nutrition (LA2400378), Ghent university, Belgium)without
any history of cardiovascular, renal or endocrine disease were included. They were judged
healthy based on physical examination and non-invasive Doppler blood pressure measure-
ment, hematology, biochemistry profile, urinalysis, and abdominal ultrasound. The cats were
between 4 and 8 years (5.29 ± 1.25 years), with a body weight ranging from 2.4 and 5.1 kg
(3.53 ± 0.78 kg; body condition score 4-5/9). Eight cats were female, 3 were male, and all of
them were neutered. The cats were housed in indoor in stable groups of 10 cats, with free access
to water, and fed a standard dry food twice a day.
Study design
The cats were premedicated with butorphanol (Dolorex, 10 mg/ml, MSD animal health) 0.2
mg/kg IV, 20 minutes before anesthesia induction. Anesthesia was induced with propofol (Pro-
povet1, 10 mg/ml, Abbott Laboratories) IV given to effect (6.30 ± 1.13 mg/kg), until endotra-
cheal intubation could be performed.Anesthesia was maintained with isoflurane vaporized in
100% oxygen, using a non-rebreathing system, to reach an end tidal isoflurane percentage of
1.2–1.4%.
All the subjects received a vasoconstrictor (AT II) and a control treatment (0.9% sodium
chloride), in a randomized order, with a washout period of 14 days. Vasoconstriction was
obtained with an infusion of AT II at a rate of 2 ng/kg/min using a syringe pump (Perfusor
Space, BBraun, Germany) for the total duration of the CEUS study and renal scintigraphy.
Cats undergoing control treatment received an infusion of sterile 0.9% sodium chloride at the
same rate and total volume as the AT II infusion. Infusion was started 5 minutes after the start
of the inhalation anesthesia. On each study day, renal perfusionwas evaluated using CEUS and
MAG3 scintigraphy, started 15 minutes after initiation of the intravenous infusion of AT II or
0.9% sodium chloride. The imaging techniques were performed in a randomized order.
Blood pressure (non-invasive Doppler measurement), heart rate, peripheral arterial oxygen
saturation, end tidal isoflurane and carbon dioxide concentrations were closely monitored.
Preparation angiotensin II
A stock solution (1000 μg/mL) was prepared by adding 1 mg of anhydrous angiotensin II
(Stigma-Aldrich,USA) to 1 mL of sterile 0.9% sodium chloride solution. This solution was fil-
tered through a 0.22 μm filter (Steriflip Vaccuum Filtration System with millipore Express
PLUS membrane, Millipore Corporation, Belgium), aliquoted into sterile cryovials (100 μL per
vial), and stored at –80°C. On the study day, 1 aliquot was thawed on ice and serially diluted in
sterile 0.9% NaCl solution to produce solutions with final concentration of 0.1 μg/mL.
Contrast-enhanced ultrasound
The hair was clipped over the ventrolateral portion of the abdomen. Alcohol and coupling gel
were applied to the skin. The US exams were performedwith the cat in dorsal recumbency.
The left kidney was centered on the screen and imaged in a longitudinal plane. The trans-
ducer was manually positioned by the same person during each imaging procedure and was
maintained at the same position during the CEUS examination.
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A 0.15 mL bolus of sulfur hexafluoride-filledmicrobubbles (Sonovue1, Bracco, Italy) was
injected into a 22-gauge indwelling catheter in the cephalic vein. The same person performed
the bolus injection in a standardized way in all cats. The ultrasound contrast agent was injected
over approximately 3 seconds followed by injection of 1 mL saline bolus. A three-way stopcock
was used to minimize any delay between the injection of microbubbles and saline. Three injec-
tions of contrast were performed: the first injection was not used for further evaluation.
Between subsequent injections, remnant microbubbles were destroyed in the caudal abdominal
aorta by setting the acoustic power at the highest level during 2 minutes.
All examinations were performed using a linear transducer of 12–5 MHz on a dedicated
machine (iU22, Philips, Bothell,WA) with contrast-specific software. Basic technical parame-
ters were a high dynamic range setting (50 dB), single focus placed directly under the kidney,
persistency off, mechanical index 0.09, timer started at the beginning of the injection. For the
gain setting, we started with a nearly dark/anechoic image, representing nearly full suppres-
sion of fundamental signal (gain: 85%). These settings were repeated during each injection.
All studies were digitally registered as a movie clip at a rate of 7 frames per second, during 90
seconds.
The clips were analyzed using specialized computer software (VueBox1, Bracco Suisse SA,
Switzerland) for objective quantitative analysis. Six regions-of-interest (ROIs) were manually
drawn: 1 on an interlobar artery, 3 in the renal cortex, 2 in the renal medulla, and a ROI con-
taining the entire kidney (Fig 1). The ROIs for the cortex and medulla were identical in size for
every clip and drawn at approximately the same depth. For every ROI, the software determined
mean pixel intensities proportional to contrast-agent concentration and created a time-inten-
sity curve. Time-intensity curveswere analyzed for peak enhancement (PE), wash-in area
under the curve (WiAUC), rise time (RT), mean transit time (mTT), time to peak (TTP),
wash-in rate (WiR), wash-in perfusion index (WiPI; WiAUC/RT), wash-out area under the
curve (WoAUC), total area under the curve (AUC), fall time (FT), and wash-out rate (WoR).
Parameters related to blood volume are PE, WiAUC, WoAUC and AUC. The PE corresponds
to the maximum contrast medium signal intensity. TheWiAUC is calculated as the sum of all
amplitudes inside the range from the beginning of the curve up to the TTP. Similarly, WoAUC
corresponds to the sum of all amplitudes inside the range from the TTP to the end of the
descending curve. The other parameters, i.e. RT, mTT, TTP, WiR, WiPI, FT, WoR, are related
to blood velocity. TheWiR andWoR represent the slopes of respectively the ascending and
descending curves. The RT corresponds to the time interval between the first arrival of contrast
and the time of peak intensity. The FT, in contrast, is the duration of contrast wash-out. Mean
transit time is the mean duration of complete contrast medium perfusion. The values for the 3
ROIs in the renal cortex and 2 ROIs in the renal medulla were averaged. Peak enhancement,
andWiAUC for the cortex, medulla and entire kidney were normalized to the values obtained
for the interlobar artery.
Scintigraphy
The cats received 124 to 137 MBq (136.18 ± 7.44 MBq) of 99mTc -MAG3 intravenously via
the cephalic vein catheter, followed by a 1 mL bolus of sterile saline flush, using the 3-way
stopcock.
The images were acquired using a gamma camera fitted with a low energy, high-resolution
collimator. The cats were positioned in dorsal recumbencywith the camera centered dorsal to
the kidneys for dynamic imaging (matrix 128x128). Dynamic scanning started simultaneously
with intravenous injection of the radiopharmaceutical. The dynamic protocol consisted of 60
frames at 1 second per frame, followed by 120 frames at 4 seconds per frame.
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Fig 1. Contrast-enhanced image of the left kidney of a cat. Note the ROIs drawn around the entire kidney, in the renal
cortex (top image), renal medulla and centered on an interlobar artery (bottom image).
doi:10.1371/journal.pone.0164488.g001
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A 30 second static image of the full and empty syringe was performed. The net amount of
injected radioactivity was determined by subtracting the amount of radioactivity in the syringe
before and after injectionmeasured in a dose calibrator.
Image frames from the dynamic acquisition for the first 30 seconds were summed. Regions
of interest were manually drawn around the left and the right kidney, and the aorta at the level
of the kidneys. Equally sized background ROIs were drawn caudal to the kidneys, excluding
major vascular structures and the lower urinary tract (Fig 2). The regions of interest were
applied to each frame and time-activity curves for the ROIs were generated. The kidney activity
was background corrected. No depth correctionwas applied. A mathematical analysis program
(Microsoft Excell) was used to determine the slopes of the kidney and aortic uptake curves.
The K/A ratio was the ratio of the initial rise of each kidney curve to the initial rise of the
arterial curve [6], using the following formula:
K=A ratio à slope of the kidney curve
slope of the aortic curve
The flow index was calculated by using the following formula [6]:
Flow index à Area under the aortic curve
Area under the kidney curve
The area under the aortic curvewas calculated from initial upslope to the point of peak
activity. The area under the kidney curvewas calculated for the same time interval.
Statistical analysis
Amixedmodel with period and treatment as categorical fixed effects and cat as random effect
was used (SAS Version 9.3). Analysis for the CEUS parameters was performed per location.
The F-test at the 5% significance level was used to assess the effect of AT II infusion on the val-
ues of the various parameters of renal blood flow obtained with CEUS and MAG3.
Results
General
Angiotensin II infusion, administration of SonoVue1 and 99mTc -MAG3 were well tolerated
and no adverse effects were noticed. Good quality images were obtained with both imaging
techniques in all study subjects.
The mean systolic blood pressure during the procedure was 88 ± 22 mmHg (ranging from
63 to 132 mmHg) for the AT II treatment and 72 ± 8 mmHg (ranging from 60–82 mmHg) for
the placebo treatment. There was a statistically significant increase (P = 0.03) in systolic blood
pressure with infusion of AT II whereas no influence of AT II infusion was noted on the heart
rate.
Contrast-enhanced ultrasound
Amean decrease of 26.1% (P = 0.04) in PE for the entire kidney and a 19.7% (P = 0.12)
decrease for the renal cortex was noticed with infusion of AT II compared to control treatment.
However, only the results for the entire kidney reached statistical significance.
Although not significant, a tendency for a lower AUC was observed after AT II infusion for
the entire kidney and renal cortex, with the effect beingmost prominent for WiAUC. A 23.2%
(P = 0.08) reduction inWiAUC was noted for the entire kidney, while a 21,3% (P = 0.15)
reduction was present for the renal cortex. Similarly, a reduction of 18.8% (P = 0.20) for the
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Fig 2. Summed dynamic dorsal images from a cat injected with 99mTc-MAG3. Note the ROIs drawn on
both kidneys with the rectangular background placed caudal to the kidneys and a rectangular ROI drawn on
the aorta at the level of the kidneys.
doi:10.1371/journal.pone.0164488.g002
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entire kidney and 21.9% (P = 0.18) for the renal cortex for theWoAUC and a reduction of
20.7% (P = 0.14; entire kidney) and 21.8% (P = 0.14; renal cortex) in total AUC were present.
None of the results reached statistical significance.
Furthermore, AT II infusion induced a significant reduction inWiPI (P = 0.04) andWoR
(P = 0.02) for the entire kidney.
The results of PE andWiAUC normalized to the interlobar artery (PE⇤ andWiAUC⇤) were
in accordance with PE andWiAUC, i.e. a decrease of these parameters was observedwith AT
II infusion. However, none of these results reached statistical significance (P-values ranging
between 0.34 and 0.22).
No changes were observed in any of the perfusion parameters for the renal medulla.
Graphs demonstrating the influence of AT II on the most important perfusion parameters
can be consulted in Fig 3. A table containing all perfusion parameters for the entire kidney,
renal cortex and medulla can be found under ‘supporting information’ (S1 Table).
Renal scintigraphy
A negligible effect of AT II was noticed on the flow index for the left kidney (4% decrease,
P = 0.52), while a 26% (P = 0.19) decrease was noted for the right kidney. K/A ratio decreased
by 16% (P = 0.22) for the left kidney and 11% (P = 0.50) for the right kidney (Fig 4, S2 Table).
However, none of the parameters reached statistical significancewhen comparing AT II infu-
sion with control treatment.
No association was observedbetween the perfusion variables obtained with CEUS and those
obtained with renal scintigraphy.
Discussion
In this study, we have shown that CEUS a promising technique is to assess perfusion changes
induced by AT II infusion in healthy cats. We found a significant decrease in PE and a ten-
dency towards a lower WiAUC compared to control measurements. Moreover a reduction in
WiPI andWoR were noticed with ATII infusion.
The physiologic effects of AT II can easily explain the AT II-induced decrease in renal blood
volume, noticed as a decrease in PE and AUC. Angiotensin II is a potent vasoconstrictor, caus-
ing an increased systemic blood pressure and evenmore important, an increased renal perfu-
sion pressure. The latter is achieved by vasoconstrictionof both the afferent and efferent
glomerular arterioles [18, 19]. Consequently, AT II causes dose-dependent decreases in total
and cortical renal blood flow [19, 20]. The efferent arteriole is more sensitive to the vasocon-
strictive effects of AT II compared to the afferent arteriole [21]. Additionally, a decreasedWiPI
andWoR were noted after AT II infusion.WiPI is calculated as a ratio of WiR and RT. In this
study, the reduction inWiPI is mainly caused by decrease inWiR. This corresponds to a slower
inflow of contrast medium, caused by AT II-induced vasoconstriction. Similarly, the reduction
inWoR corresponds to slower outflow of contrast medium.
In our study, infusion of AT II did not alter any of the perfusion parameters for the renal
medulla. Studies performed on rats using invasive laser Doppler perfusionmonitoring, report
an inconsistent effect of angiotensin on the medullary blood flow varying from no influence to
an increase in medullary blood flow [20, 22, 23]. The exact etiology remains unclear: a higher
concentration of vasodilatory substances as prostaglandins, kinins and nitrogen oxide in the
renal medulla,may likely cause this phenomenon [20, 23].
Our results are in accordance with a study in humans where a dose-dependent decrease in
perfusion index of the renal cortex was observedwith CEUS after infusion of AT II. The
changes in perfusion index paralleled those in estimated renal plasma flowmeasured with
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Fig 3. Changes in CEUS parameters induced by angiotensin II. presented as means +/- standard error.
* p value  0.05. From left to right, top to bottom: peak enhancement (PE), ratio of peak enhancement with
interlobar artery (PE*), wash-in area-under-the-curve (WiAUC), total area-under-the-curve (total AUC),
wash-out area-under-the-curve (WoAUC), wash-in perfusion index (WiPI) and wash-out-rate (WoR). All
parameters are expressed in arbitrary units.
doi:10.1371/journal.pone.0164488.g003
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PAH-clearance techniques [24]. In a recent study in sheep, a very heterogeneous and inconsis-
tent response on CEUS parameters was noticed after infusion of AT II. The only significant
finding was an increase in mean transit time, corresponding with a delayed replenishment,
caused by a high dose AT II infusion [25]. In both the human and sheep study, CEUS was per-
formed using continuous infusion of contrast agent followed by several destruction-refilling
sequences, whereas in our study a bolus injectionwas performed. Therefore, different perfusion
parameters are obtained in the current study compared to the human and sheep study, and
thus exact comparison of the results is not possible.
The discrepancy between the flow index for the left and right kidney is most likely related to
inclusion of liver activity in the ROI for the right kidney. Variable hepatic uptake of 99mTc-
MAG3 has been described in cats [26]. The anatomic location of the right kidney close to the
caudate lobe of the liver complicates complicated complete exclusion of liver activity within the
renal ROI.
We did not observe an association between any of the CEUS parameters and values
obtained with 99mTc-MAG3 scintigraphy. Perfusion changes induced by ATII did not reach
statistical significancewith renal scintigraphy. In a study with human patients with various
renal diseases, a significant correlation was present between ERPF determined by PAH-clear-
ance, ERPF determined by 99mTc-MAG3 scintigraphy and decline ratio obtained with CEUS.
However, no association was seen between the peak intensity obtained with CEUS, scintigra-
phy and PAH-clearance. Contrast-enhanced ultrasound in the latter study was performed
using a combination of harmonic power Doppler and intermittent imaging during a continu-
ous infusion of contrast agent [27]. A strict comparison betweenCEUS and renal scintigraphy
is impossible because with CEUS regional blood flow is determined on a microvascular level
while total renal blood flow on a macrovascular level is assessed using renal scintigraphy.
Moreover, both techniques only deliver relative perfusion parameters, as no formulas exist to
calculate effective or estimated renal plasma flow derived from these techniques in cats. Differ-
ent perfusion parameters are calculated from both techniques, further complicating a compari-
son. Furthermore, there is a high heterogeneity in the parameters that are determined by
CEUS. The assessed parameters depend on the injection procedure: different parameters are
calculated using continuous infusing of contrast-agent compared by bolus injection. It may be
Fig 4. Changes in scintigraphic perfusion parameters induced by angiotensin II. presented as means +/- standard error. LK: left
kidney, RK: right kidney.
doi:10.1371/journal.pone.0164488.g004
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assumed that constant infusion studies would suffer from less variability because constant infu-
sions are performed using an infusion pump while bolus injections are performedmanually.
However, no data are available to support this hypothesis. Bolus injection has the major advan-
tage that it is easy to administer and less cumbersome.
This study has some limitations. Although there is a gold standard for global renal plasma
flow evaluation (PAH), there is not one for microperfusion. Laser Doppler probes have been
used in rats for evaluation of global renal perfusion as well as cortical and medullary perfusion
[20, 22, 23]. However, the technique has not been described in cats and is due to its invasive-
ness unethical to use. Renal scintigraphy using 99mTc-MAG3 is the only non-invasive technique
available for evaluation of perfusion in cats. Data on the use of renal scintigraphy in cats is lim-
ited and no formula is established to determine ERPF as available in dogs and human.
Second, anesthesia might suppress the effect of angiotensin II. Therefore, the response of
the anesthetized cats in this study might differ from the response that would be seen in con-
scious cats. We choose to anesthetize the cats to eliminate the variable and unpredictable varia-
tions in blood pressure caused by stress. In a murine study, barbiturate anesthesia was found to
decrease baseline arterial pressure, however it did not alter the response to AT II [28]. In sheep,
isoflurane anesthesia reduced the hypertensive response to AT II both in magnitude and dura-
tion, however the reduction in renal blood flow was similar to conscious animals [29].
In this study we established a dose of AT II inducing detectable perfusion changes with
CEUS, whereas no significant perfusion changes could be observedwith renal scintigraphy.
Future research, using multiple doses of AT II could be performed to assess the sensitivity of
both techniques.
Finally, it is recommended to reduce variations in intensity dependedCEUS parameters, as
PE and AUC, by normalization of areas of interest with neighboring normal tissue, resulting in
a ratio between the ROI and reference tissue [30, 31]. Reference tissue for the left kidney could
be the abdominal aorta or the spleen. However, it is impossible to obtain a reproducible image
of the kidney while simultaneously imaging the aorta or spleen in the same imaging plane. In
this study, normalization to an interlobar vessel was tested. The major problem is that the
interlobar vessels are also influenced by AT II infusion.Moreover, due to their small size, they
are difficult to image and to correctly place a ROI, leading to relatively high variability.
Conclusion
This study demonstrates that CEUS is a potentially valuable technique to detect changes in
feline renal perfusion after infusion of AT II. These perfusion changes were not depicted by
renal scintigraphy. Further research is warranted to determine the value of CEUS for diagnosis
of naturally occurringdiffuse renal pathology.
Supporting Information
S1 Table. Mean and Standard Errors values of renal CEUS perfusion variables of the left
kidney, for the entire kidney, cortex and medulla. †value represents a significant (P<0.05)
effect (PE peak enhancement, PE⇤ peak enhancement relative to interlobar artery, WiAUC
wash-in area-under-the-curve,WiAUC⇤ wash-in area-under-the-curve relative to artery, RT
rise time, mTT mean transit time, TTP time to peak,WiR wash-in rate, WiPI wash-in perfu-
sion index,WoAUC wash-out area-under-the-curve,AUC total area-under-the-curve, FT fall
time,WoR wash-out rate)
(PDF)
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S2 Table. Mean and Standard Errors for 99mTc-MAG3 scintigraphy parameters.Percentage
uptake and kidney-to-heart ratio (K/A) for the left and right kidney separately.
(PDF)
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